Literature DB >> 22316618

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.

U Mallick, C Harmer, A Hackshaw, L Moss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22316618     DOI： 10.1016/j.clon.2012.01.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  17 in total

1.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

2.  Cost-effectiveness of (99m)Tc-MIBI in the evaluation of thyroid nodules for malignancy: a new lease of life for an old radiopharmaceutical?

Authors:  Frederik A Verburg; Florian F Behrendt; Felix M Mottaghy; Alexander Heinzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-11       Impact factor: 9.236

3.  Clinical trials in molecular radiotherapy-Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018.

Authors:  Nadia Falzone; Rebecca Gregory; Matthew Aldridge; Samantha Ya Terry; Glenn Flux
Journal:  Br J Radiol       Date:  2019-05-20       Impact factor: 3.039

4.  Radioiodine - the success story of Nuclear Medicine : 75th Anniversary of the first use of Iodine-131 in humans.

Authors:  V Ralph McCready
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02       Impact factor: 9.236

Review 5.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.

Authors:  Elena-Daphne Thies; Karina Tanase; Uwe Maeder; Markus Luster; Andreas K Buck; Heribert Hänscheid; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-17       Impact factor: 9.236

8.  Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer.

Authors:  Samuel Chan; Katarina Karamali; Anna Kolodziejczyk; Georgios Oikonomou; John Watkinson; Vinidh Paleri; Iain Nixon; Dae Kim
Journal:  Eur Thyroid J       Date:  2020-01-28

9.  Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Anneke C Muller Kobold; Bruce H R Wolffenbuttel; John T M Plukker; Peter H Bisschop; John M de Klerk; Imad Al Younis; Paul Lips; Jan W Smit; Adrienne H Brouwers; Thera P Links
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.